Answers are grounded in this paper and cite their sources.
Comparative analyses reveal treatment effects in relapsed/refractory multiple myeloma patients, suggesting Talquetamab may enhance outcomes.
MonumenTAL‑1, ClinicalTrials.gov identifier NCT03399799/NCT04634552; LocoMMotion, ClinicalTrials.gov identifier NCT04035226; MoMMent, ClinicalTrials.gov identifier NCT05160584.
No takes yet. Share an insight, caveat, or question.
Vincent et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: